Vivus (VVUS) says Phase III data published on its Qnexa obesity drug showed a 14.4% average...

|By:, SA News Editor

Vivus (VVUS) says Phase III data published on its Qnexa obesity drug showed a 14.4% average weight loss in severely obese patients completing one year of treatment. VVUS +3.8% premarket.